-+ 0.00%
-+ 0.00%
-+ 0.00%
Sandoz Begins US Sale of Retinal Diseases Drug Enzeevu
Share
Listen to the news
01:38 AM EST, 11/16/2026 (MT Newswires) -- Sandoz Group (SDZ.SW) started the sale in the US of retinal disease medication aflibercept-abzv under the brand name Enzeevu, according to a Monday release. The Switzerland-listed drugmaker is selling the medication as a 2-milligram pre-filled syringe. The drug is based on the reference medicine Eylea, or aflibercept, and is indicated for various retinal diseases, including neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic retinopathy, and diabetic macular edema. In line with the US launch, Sandoz agreed to manufacture Enzeevu for private-label commercialization under a multi-year agreement commencing in mid-2027.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending